ACS CAN advocates for policies that provide access to treatments and services people with cancer need for their care - including those who may be newly diagnosed, in active treatment and cancer survivors.
This ACS CAN report focuses specifically on the costs of cancer borne by patients in active treatment as well as survivors. It examines the factors contributing to the cost of cancer care, the type of direct costs patients pay, and the indirect costs associated with cancer.
This Survivor Views survey examined access to and affordability of cancer care. Survivors report insurance-related barriers to obtaining prescriptions, and lower-income respondents in particular have difficulty affording them. 24% of respondents have received a surprise medical bill, 60% of which were more than $500.
Biological drugs, commonly referred to as biologics, are a class of drugs that are produced using a living system, such as a microorganism, plant cell, or animal cell. Like all drugs, biologics are regulated by the United States Food and Drug Administration (FDA).
For an individual with specific health care needs – like cancer patients and survivors – the drugs covered by a health plan and corresponding cost sharing for each drug is important information when choosing health insurance. However, to make an informed choice, formulary information must be disclosed to the individual.
The American Cancer Society Cancer Action Network (ACS CAN) submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the Medicare Drug Price Negotiation Initial Price Applicability Year (IPAY) 2028 public engagement process, including results from patient-experience surveys
The American Cancer Society and the American Cancer Society Cancer Action Network provided joint comments to CMS on the the proposed decision memo for changes to the existing National Coverage Decision (NCD) 210.3 related to screening for colorectal cancer (CRC) using non-invasive biomarker tests
ACS CAN joined with 50 other organizations to applaud Representatives Jodey Arrington (R-TX) and Terri Sewell (D-AL) for sponsoring and prioritizing the passage of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (H.R. 842).
This ACS CAN chartbook provides cancer-specific data related to Medicare, including basic information about the program, a discussion of its components, characteristics of enrollees, coverage of services – specifically those related to prevention and screening – program expenditures and enrollees
ACS CAN submitted comments strongly supporting several policy changes that will make it easier to apply for, enroll in, and maintain enrollment in Medicaid and CHIP.
